Effect of S-1 combined with oxaliplatin on serum tumor markers,matrix metalloproteinase and immune function in elderly patients with gastric cancer

摘要

Objective: To investigate the effect of Compound Tegafur and Oteracil Potassium Sustained Capsules (S-1) combined with oxaliplatin chemotherapy on serum tumor marker matrix metalloproteinase and immune function in elderly patients with gastric cancer. Methods:According to the random data table, 80 cases of elderly patients with gastric cancer were divided into control group and observation group (n=40), patients in the control group were treated with oxaliplatin combined with Capecitabine Tablets, and the observation group patients were treated with S-1 combined with oxaliplatin, all treated for 6 cycles, before and after treatment, levels of serum tumor markers, matrix metalloproteinase and immune function were compared between the two groups. Results: Before treatment, there was no significant difference in the levels of CEA, CA125, CA19-9, MMP-2, MMP-9, CD3+, CD4+, CD8+and CD4+/CD8+between the two groups;After treatment, the levels of CEA, CA125, CA19-9, MMP-2, MMP-9 and CD8+in the two groups were significantly lower than those in the same group before treatment, and the levels of the observation group[(7.79±2.78) ng/mL, (22.56±7.31) U/mL, (13.48±3.05) U/mL, (57.84±8.93) ng/mL, (199.14±67.39) ng/mL and (26.21±4.18)%] were significantly lower than those in the control group;Compared with the group before treatment, the levels of CD3+, CD4+and CD4+/CD8+in the two groups were significantly increased, and the observation group [(66.89±5.84)%, (41.63±5.24)% and (1.37±0.29)] was significantly higher than the control group. Conclusion: S-1 combined with oxaliplatin chemotherapy can effectively reduce serum tumor markers and matrix metalloproteinase levels, improve immune function, has an important clinical value.